Evidence Snapshot

Retinoic acid receptor

CHEMBL2363069 PROTEIN FAMILY Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:31Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:25 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2363069

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Retinoic acid receptor as ChEMBL target CHEMBL2363069, mapped to UniProt P13631. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Retinoic acid receptor

PROTEIN FAMILY · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2363069

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P13631

Retinoic acid receptor gamma

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Retinoic acid receptor matters

As of 2026-09-13

Retinoic acid receptor is reviewed as Retinoic acid receptor gamma (UniProt P13631); Retinoic acid receptor shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 29 compounds, and 14 assays, with lead potency reaching pChEMBL 9.0.

Protein context

Retinoic acid receptor gamma

Retinoic acid receptor gamma Sequence length is 454 aa.

Review this target as Retinoic acid receptor, mapped to UniProt P13631. ChEMBL maps the protein component as Retinoic acid receptor gamma. Sequence length is 454 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P13631 Protein

Disease context

acne

Retinoic acid receptor shows approved-linked disease relevance led by acne. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ADAPALENE, ISOTRETINOIN, TAZAROTENE.

Start review with acne because it currently carries approved-linked support. Linked drugs include ADAPALENE, ISOTRETINOIN, TAZAROTENE, TRETINOIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 4 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 29 compounds, and 14 assays for this target. The dominant activity type is EC50. CHEMBL38 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL38 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine

1 approved pChEMBL 9.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Retinoic acid receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P13631, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acne is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

IC50: 1.0, EC50: 2.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure	Compound	pChEMBL	Type	Phase
	No preferred name CHEMBL38	9.0	EC50	Approved